Do Analysts Agree Wednesday on Day One Biopharmaceuticals Inc (DAWN) Stock's Target Price?

Wall Street is positive on Day One Biopharmaceuticals Inc (DAWN). On average, analysts give the stock a Strong Buy rating. The average price target is $33, which means analysts expect the stock to climb by 235.71% over the next twelve months. That average ranking earns the stock an Analyst Rating of 73, which is better than 73% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating DAWN a Strong Buy today. Find out what this means to you and get the rest of the rankings on DAWN!

See Full DAWN Report

Why are Analyst Ratings Important?

Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions before a quarterly report that could be worse than expected. InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.

What's Happening With Day One Biopharmaceuticals Inc Stock Today?

Day One Biopharmaceuticals Inc (DAWN) stock has gained 2.08% while the S&P 500 is lower by -0.63% as of 4:00 PM on Wednesday, Mar 30. DAWN is higher by $0.20 from the previous closing price of $9.63 on volume of 100,114 shares. Over the past year the S&P 500 has risen 9.56% while DAWN is lower by -62.03%. DAWN lost -$3.00 per share the over the last 12 months. Click Here to get the full Stock Report for Day One Biopharmaceuticals Inc stock.